Why did Aclaris Therapeutics' operating expenses drop sharply in Q4 2024?

Aclaris Therapeutics' operating expenses decreased significantly in Q4 2024 primarily due to a reduction in compensation-related expenses resulting from lower headcount and higher forfeiture credits. This decrease in operating expenses reflects the company's strategic measures to optimize its resource allocation and reduce costs without compromising its clinical development initiatives.